1
|
Bickett TE, Knitz MW, Piper M, Oweida AJ, Gadwa J, Darragh LB, Nguyen D, Bhatia S, Bhuvane S, Phan AV, Van Court B, Corbo S, Pham T, Dent AL, Lenz L, Karam SD. Dichotomous effects of cellular expression of STAT3 on tumor growth of HNSCC. Mol Ther 2022; 30:1149-1162. [PMID: 34793974 PMCID: PMC8899526 DOI: 10.1016/j.ymthe.2021.11.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2021] [Revised: 10/17/2021] [Accepted: 11/11/2021] [Indexed: 01/12/2023] Open
Abstract
STAT3 signaling has been shown to regulate cellular function and cytokine production in the tumor microenvironment (TME). Within the head and neck squamous cell carcinoma (HNSCC) TME, we previously showed that therapeutic targeting of STAT3 in combination with radiation resulted in improved tumor growth delay. However, given the independent regulatory effects STAT3 has on anti-tumor immunity, we aimed to decipher the effects of individually targeting STAT3 in the cancer cell, regulatory T cells (Tregs), and natural killer (NK) cell compartments in driving tumor growth and resistance to therapy in HNSCCs. We utilized a CRISPR knockout system for genetic deletion of STAT3 within the cancer cell as well as two genetic knockout mouse models, FoxP3-Cre/STAT3 fl and NKp46-Cre/STAT3 fl, for Tregs and NK cell targeting, respectively. Our data revealed differences in development of resistance to treatment with STAT3 CRISPR knockout in the cancer cell, driven by differential recruitment of immune cells. Knockout of STAT3 in Tregs overcomes this resistance and results in Treg reprogramming and recruitment and activation of antigen-presenting cells. In contrast, knockout of STAT3 in the NK cell compartment results in NK cell inactivation and acceleration of tumor growth. These data underscore the complex interplay between the cancer cell and the immune TME and carry significant implications for drug targeting and design of combination approaches in HNSCCs.
Collapse
Affiliation(s)
- Thomas E Bickett
- Department of Radiation Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
| | - Michael W Knitz
- Department of Radiation Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
| | - Miles Piper
- Department of Radiation Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
| | - Ayman J Oweida
- Département de Médecine Nucléaire et Radiobiologie, Université de Sherbrooke, Sherbrooke, Quebec J1K 2R1, Canada
| | - Jacob Gadwa
- Department of Radiation Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
| | - Laurel B Darragh
- Department of Radiation Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; Department of Immunology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
| | - Diemmy Nguyen
- Department of Radiation Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
| | - Shilpa Bhatia
- Department of Radiation Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
| | - Shiv Bhuvane
- Department of Radiation Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
| | - Andy V Phan
- Department of Radiation Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
| | - Benjamin Van Court
- Department of Radiation Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
| | - Sophia Corbo
- Department of Radiation Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
| | - Tiffany Pham
- Department of Otolaryngology, Head and Neck Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
| | - Alexander L Dent
- Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - Laurel Lenz
- Department of Immunology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
| | - Sana D Karam
- Department of Radiation Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; Department of Immunology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
| |
Collapse
|
3
|
Almeida FF, Tognarelli S, Marçais A, Kueh AJ, Friede ME, Liao Y, Willis SN, Luong K, Faure F, Mercier FE, Galluso J, Firth M, Narni-Mancinelli E, Rais B, Scadden DT, Spallotta F, Weil S, Giannattasio A, Kalensee F, Zöller T, Huntington ND, Schleicher U, Chiocchetti AG, Ugolini S, Herold MJ, Shi W, Koch J, Steinle A, Vivier E, Walzer T, Belz GT, Ullrich E. A point mutation in the Ncr1 signal peptide impairs the development of innate lymphoid cell subsets. Oncoimmunology 2018; 7:e1475875. [PMID: 30288342 PMCID: PMC6169588 DOI: 10.1080/2162402x.2018.1475875] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2018] [Revised: 06/01/2018] [Accepted: 05/07/2018] [Indexed: 01/06/2023] Open
Abstract
NKp46 (CD335) is a surface receptor shared by both human and mouse natural killer (NK) cells and innate lymphoid cells (ILCs) that transduces activating signals necessary to eliminate virus-infected cells and tumors. Here, we describe a spontaneous point mutation of cysteine to arginine (C14R) in the signal peptide of the NKp46 protein in congenic Ly5.1 mice and the newly generated NCRB6C14R strain. Ly5.1C14R NK cells expressed similar levels of Ncr1 mRNA as C57BL/6, but showed impaired surface NKp46 and reduced ability to control melanoma tumors in vivo. Expression of the mutant NKp46C14R in 293T cells showed that NKp46 protein trafficking to the cell surface was compromised. Although Ly5.1C14R mice had normal number of NK cells, they showed an increased number of early maturation stage NK cells. CD49a+ILC1s were also increased but these cells lacked the expression of TRAIL. ILC3s that expressed NKp46 were not detectable and were not apparent when examined by T-bet expression. Thus, the C14R mutation reveals that NKp46 is important for NK cell and ILC differentiation, maturation and function. Significance Innate lymphoid cells (ILCs) play important roles in immune protection. Various subsets of ILCs express the activating receptor NKp46 which is capable of recognizing pathogen derived and tumor ligands and is necessary for immune protection. Here, we describe a spontaneous point mutation in the signal peptide of the NKp46 protein in congenic Ly5.1 mice which are widely used for tracking cells in vivo. This Ncr1 C14R mutation impairs NKp46 surface expression resulting in destabilization of Ncr1 and accumulation of NKp46 in the endoplasmic reticulum. Loss of stable NKp46 expression impaired the maturation of NKp46+ ILCs and altered the expression of TRAIL and T-bet in ILC1 and ILC3, respectively.
Collapse
Affiliation(s)
- Francisca F Almeida
- Division of Molecular Immunology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.,Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia
| | - Sara Tognarelli
- Division of Stem Cell Transplantation and Immunology, Department for Children and Adolescents Medicine, Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany.,LOEWE Center for Cell and Gene Therapy, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
| | - Antoine Marçais
- CIRI, Centre International de Recherche en Infectiologie - International Center for Infectiology Research, Inserm, U1111, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon 1, Lyon, France
| | - Andrew J Kueh
- Division of Molecular Immunology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.,Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia
| | - Miriam E Friede
- Institute for Molecular Medicine, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
| | - Yang Liao
- Division of Molecular Immunology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.,Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia
| | - Simon N Willis
- Division of Molecular Immunology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.,Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia
| | - Kylie Luong
- Division of Molecular Immunology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.,Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia
| | - Fabrice Faure
- CIRI, Centre International de Recherche en Infectiologie - International Center for Infectiology Research, Inserm, U1111, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon 1, Lyon, France
| | | | - Justine Galluso
- CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, Aix Marseille University, Marseille, France
| | - Matthew Firth
- Division of Molecular Immunology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.,Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia
| | - Emilie Narni-Mancinelli
- CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, Aix Marseille University, Marseille, France
| | - Bushra Rais
- Division of Stem Cell Transplantation and Immunology, Department for Children and Adolescents Medicine, Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany.,LOEWE Center for Cell and Gene Therapy, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
| | | | - Francesco Spallotta
- Division of Cardiovascular Epigenetics, Department of Cardiology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
| | - Sandra Weil
- Georg Speyer Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany.,Institute of Medical Microbiology and Hygiene, University of Mainz Medical Center, Mainz, Germany
| | - Ariane Giannattasio
- Georg Speyer Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany.,Institute of Medical Microbiology and Hygiene, University of Mainz Medical Center, Mainz, Germany
| | - Franziska Kalensee
- Division of Stem Cell Transplantation and Immunology, Department for Children and Adolescents Medicine, Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany.,LOEWE Center for Cell and Gene Therapy, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
| | - Tobias Zöller
- Institute for Molecular Medicine, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
| | - Nicholas D Huntington
- Division of Molecular Immunology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.,Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia
| | - Ulrike Schleicher
- Mikrobiologisches Institut-Klinische Mikrobiologie, Immunologie und Hygiene, Friedrich-Alexander-Universität Erlangen-Nürnberg und Universitätsklinikum Erlangen, Erlangen, Germany
| | - Andreas G Chiocchetti
- Molecular Genetics Laboratory, Department for Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
| | - Sophie Ugolini
- CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, Aix Marseille University, Marseille, France
| | - Marco J Herold
- Division of Molecular Immunology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.,Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia
| | - Wei Shi
- Division of Molecular Immunology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.,Department of Computing and Information Systems, University of Melbourne, Melbourne, Victoria, Australia
| | - Joachim Koch
- Georg Speyer Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany.,Institute of Medical Microbiology and Hygiene, University of Mainz Medical Center, Mainz, Germany
| | - Alexander Steinle
- Institute for Molecular Medicine, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
| | - Eric Vivier
- CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, Aix Marseille University, Marseille, France.,Innate Pharma, Marseille, France.,Service d'Immunologie, Hôpital de la Timone, Marseille Immunopole, Assistance Publique - Hôpitaux de Marseille, Marseille, France
| | - Thierry Walzer
- CIRI, Centre International de Recherche en Infectiologie - International Center for Infectiology Research, Inserm, U1111, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon 1, Lyon, France
| | - Gabrielle T Belz
- Division of Molecular Immunology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.,Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia
| | - Evelyn Ullrich
- LOEWE Center for Cell and Gene Therapy, Johann Wolfgang Goethe University, Frankfurt am Main, Germany.,Division of Stem Cell Transplantation and Immunology, Department for Children and Adolescents Medicine, Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany
| |
Collapse
|
4
|
McQuaid S, Loughran S, Power P, Maguire P, Walls D, Cusi MG, Orvell C, Johnson P. Haemagglutinin-neuraminidase from HPIV3 mediates human NK regulation of T cell proliferation via NKp44 and NKp46. J Gen Virol 2018; 99:763-767. [PMID: 29683419 DOI: 10.1099/jgv.0.001070] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
HPIV3 is a respiratory virus causing airway diseases, including pneumonia, croup, and bronchiolitis, during infancy and childhood. Currently there is no effective vaccine or anti-viral therapy for this virus. Studies have suggested that poor T cell proliferation following HPIV3 infection is responsible for impaired immunological memory associated with this virus. We have previously demonstrated that NK cells mediate regulation of T cell proliferation during HPIV3 infection. Here we add to these studies by demonstrating that the regulation of T cell proliferation during HPIV3 infection is mediated via NK receptors NKp44 and NKp46 and involves the surface glycoprotein haemagglutinin-neuraminidase but not the fusion protein of the virus. These studies extend our knowledge of the regulatory repertoire of NK cells and provide mechanistic insights which may explain reoccurring failures of vaccines against this virus.
Collapse
Affiliation(s)
- Samantha McQuaid
- Viral Immunology Laboratory, School of Nursing and Human Sciences, Dublin City University, Glasnevin, Dublin 9, Ireland.,Present address: Mason Technology Ltd., Dublin, Ireland
| | - Sinead Loughran
- Viral Immunology Laboratory, School of Nursing and Human Sciences, Dublin City University, Glasnevin, Dublin 9, Ireland., Department of Applied Science, Dundalk Institute of Technology, Co. Louth, Ireland
| | - Patrick Power
- Viral Immunology Laboratory, School of Nursing and Human Sciences, Dublin City University, Glasnevin, Dublin 9, Ireland.,Dublin Institute of Technology, Dublin, Ireland
| | - Paula Maguire
- Viral Immunology Laboratory, School of Nursing and Human Sciences, Dublin City University, Glasnevin, Dublin 9, Ireland
| | - Dermot Walls
- Molecular Virology Laboratory, School of Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
| | - Maria Grazia Cusi
- Department of Molecular Biology, Section of Microbiology, University of Siena, Via Laterina 8, IT - 53100 Siena, Italy
| | - Claes Orvell
- Division of Clinical Virology, F68, Karolinska University Hospital, SE-141 86 Stockholm, Sweden
| | - Patricia Johnson
- Viral Immunology Laboratory, School of Nursing and Human Sciences, Dublin City University, Glasnevin, Dublin 9, Ireland
| |
Collapse
|
5
|
Jang Y, Gerbec ZJ, Won T, Choi B, Podsiad A, B Moore B, Malarkannan S, Laouar Y. Cutting Edge: Check Your Mice-A Point Mutation in the Ncr1 Locus Identified in CD45.1 Congenic Mice with Consequences in Mouse Susceptibility to Infection. THE JOURNAL OF IMMUNOLOGY 2018; 200:1982-1987. [PMID: 29440507 DOI: 10.4049/jimmunol.1701676] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/13/2017] [Accepted: 01/21/2018] [Indexed: 12/31/2022]
Abstract
B6.SJL-Ptprca Pepcb /Boy (CD45.1) mice have been used in hundreds of congenic competitive transplants, with the presumption that they differ from C57BL/6 mice only at the CD45 locus. In this study, we describe a point mutation in the natural cytotoxicity receptor 1 (Ncr1) locus fortuitously identified in the CD45.1 strain. This point mutation was mapped at the 40th nucleotide of the Ncr1 locus causing a single amino acid mutation from cysteine to arginine at position 14 from the start codon, resulting in loss of NCR1 expression. We found that these mice were more resistant to CMV due to a hyper innate IFN-γ response in the absence of NCR1. In contrast, loss of NCR1 increased susceptibility to influenza virus, a result that is consistent with the role of NCR1 in the recognition of influenza Ag, hemagglutinin. This work sheds light on potential confounding experimental interpretation when this congenic strain is used as a tool for tracking lymphocyte development.
Collapse
Affiliation(s)
- Youngsoon Jang
- Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI 48109
| | - Zachary J Gerbec
- Blood Center of Wisconsin, Milwaukee, WI 53226.,Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226.,Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI 53226.,Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226; and
| | - Taejoon Won
- Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI 48109
| | - Bongkum Choi
- Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI 48109
| | - Amy Podsiad
- Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109
| | - Bethany B Moore
- Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI 48109.,Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109
| | - Subramaniam Malarkannan
- Blood Center of Wisconsin, Milwaukee, WI 53226.,Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226.,Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI 53226.,Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226; and
| | - Yasmina Laouar
- Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI 48109;
| |
Collapse
|
6
|
Glasner A, Oiknine-Djian E, Weisblum Y, Diab M, Panet A, Wolf DG, Mandelboim O. Zika Virus Escapes NK Cell Detection by Upregulating Major Histocompatibility Complex Class I Molecules. J Virol 2017; 91:e00785-17. [PMID: 28878071 PMCID: PMC5660495 DOI: 10.1128/jvi.00785-17] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2017] [Accepted: 08/21/2017] [Indexed: 12/11/2022] Open
Abstract
NK cells are innate lymphocytes that participate in many immune processes encompassing cancer, bacterial and fungal infection, autoimmunity, and even pregnancy and that specialize in antiviral defense. NK cells express inhibitory and activating receptors and kill their targets when activating signals overpower inhibitory signals. The NK cell inhibitory receptors include a uniquely diverse array of proteins named killer cell immunoglobulin-like receptors (KIRs), the CD94 family, and the leukocyte immunoglobulin-like receptor (LIR) family. The NK cell inhibitory receptors recognize mostly major histocompatibility complex (MHC) class I (MHC-I) proteins. Zika virus has recently emerged as a major threat due to its association with birth defects and its pandemic potential. How Zika virus interacts with the immune system, and especially with NK cells, is unclear. Here we show that Zika virus infection is barely sensed by NK cells, since little or no increase in the expression of activating NK cell ligands was observed following Zika infection. In contrast, we demonstrate that Zika virus infection leads to the upregulation of MHC class I proteins and consequently to the inhibition of NK cell killing. Mechanistically, we show that MHC class I proteins are upregulated via the RIGI-IRF3 pathway and that this upregulation is mediated via beta interferon (IFN-β). Potentially, countering MHC class I upregulation during Zika virus infection could be used as a prophylactic treatment against Zika virus.IMPORTANCE NK cells are innate lymphocytes that recognize and eliminate various pathogens and are known mostly for their role in controlling viral infections. NK cells express inhibitory and activating receptors, and they kill or spare their targets based on the integration of inhibitory and activating signals. Zika virus has recently emerged as a major threat to humans due to its pandemic potential and its association with birth defects. The role of NK cells in Zika virus infection is largely unknown. Here we demonstrate that Zika virus infection is almost undetected by NK cells, as evidenced by the fact that the expression of activating ligands for NK cells is not induced following Zika infection. We identified a mechanism whereby Zika virus sensing via the RIGI-IRF3 pathway resulted in IFN-β-mediated upregulation of MHC-I molecules and inhibition of NK cell activity. Countering MHC class I upregulation and boosting NK cell activity may be employed as prophylactic measures to combat Zika virus infection.
Collapse
Affiliation(s)
- Ariella Glasner
- Lautenberg Center for General and Tumor Immunology, Department of Immunology and Cancer Research, IMRIC, Faculty of Medicine, The Hebrew University Medical School, Jerusalem, Israel
| | - Esther Oiknine-Djian
- Clinical Virology Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel
| | - Yiska Weisblum
- Clinical Virology Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel
| | - Mohammad Diab
- Lautenberg Center for General and Tumor Immunology, Department of Immunology and Cancer Research, IMRIC, Faculty of Medicine, The Hebrew University Medical School, Jerusalem, Israel
| | - Amos Panet
- Department of Biochemistry and Chanock Center for Virology, IMRIC, Faculty of Medicine, The Hebrew University Jerusalem, Israel
| | - Dana G Wolf
- Clinical Virology Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel
| | - Ofer Mandelboim
- Lautenberg Center for General and Tumor Immunology, Department of Immunology and Cancer Research, IMRIC, Faculty of Medicine, The Hebrew University Medical School, Jerusalem, Israel
| |
Collapse
|